AI assistant
ImmunityBio, Inc. — Director's Dealing 2024
Feb 7, 2024
31529_dirs_2024-02-06_1df186ee-f3b8-4b39-985f-2685bcea21ca.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ImmunityBio, Inc. (IBRX)
CIK: 0001326110
Period of Report: 2024-02-05
Reporting Person: Adcock Richard (Director, CEO & President)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-02-05 | Common Stock | M | 83334 | — | Acquired | 286303 | Direct |
| 2024-02-05 | Common Stock | F | 43165 | $4.04 | Disposed | 243138 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-02-05 | Restricted Stock Units | $ | M | 83334 | Disposed | Common Stock (83334) | Direct |
Footnotes
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.
F2: Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 83,333 of the shares subject to the RSU award vested in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 83,334 of the shares vested on the third anniversary of the vesting commencement date, such that all shares were vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award was February 5, 2021.